Ventrus Biosciences Inc
(NASDAQ: VTUS)
+0.09
+3.37%
| Exchange: | NASDAQ |
| Stock: | Ventrus Biosciences Inc |
| Industry: | Drug Manufacturers - Major |
| Employees: | 8 |
| Ventrus Biosciences, Inc. (Ventrus) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Its product candidate portfolio consists of three late-stage drugs intended to treat these conditions: one new chemical entity (NCE) and two previously approved molecules that will have market exclusivity for new and patentable topical gastrointestinal indications. The Company’s three late-stage product candidates are Iferanserin ointment (VEN 309) for the treatment of hemorrhoids, Diltiazem cream (VEN 307), a treatment for the relief of pain associated with anal fissures and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis (IPAA). On November 14, 2011, the Company acquired Sam Amer & Co. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
